|
|
Post by uvula on Jan 15, 2019 11:46:49 GMT -5
When did Mike get a phd?
|
|
|
|
Post by awesomo on Jan 15, 2019 12:07:29 GMT -5
|
|
|
|
Post by akemp3000 on Jan 15, 2019 12:17:11 GMT -5
When you see a PharmD, Masters in Business from Wharton and impressive global experience on a cv then add CEO of the year in pharmacy, it's quite a stretch to suggest Mike doesn't get it. IMO, he's had an impressive start turning this company around and giving it better guidance and optimism in under two years. The pps hasn't caught up just yet but...The future's so bright we gotta wear shades  |
|
|
|
Post by #NoMoreNeedles on Jan 15, 2019 12:53:59 GMT -5
Celgene almost collapsed financially. A few days ago they were acquired for lots of money! MannKind is now a 3-5 long-term investment story. If you cannot stomach to loose everything, go buy Berkshire Hathaway Series A.
|
|
|
|
Post by wgreystone on Jan 15, 2019 12:55:46 GMT -5
And we need people like Sports who has been dedicated to getting out the good word about our undervalued investment - and without any pay. So take a chill pill Kudos for efforts to promote Afrezza, which should be promoted. But history of getting out word about "undervalued" investment has led to a lot of people suffering significant loses... as the word about being undervalued has existed since MNKD has been at split adjusted price of over $50. Given the limited money available for marketing Afrezza, script will grow slowly but steadily. So don't believe the hype from Mike K. for lofty near term SP target. Once TreT is approved, MNKD will get good royalty payment, SP will likely start to fly by then. |
|
|
|
Post by buyitonsale on Jan 17, 2019 1:06:16 GMT -5
Yes, low 20M based on Afrezza US sales only. I’m betting this number will be higher with ex US sales and we will have a first profitable sales quarter in 2020. Speaking of profitable quarters... Q4 18 ER is coming up. Wonder if under a dollar holds until then ? 😊 I think most of the carnage has happened. I would expect the conference call to discuss the latest funding. Right at the end Mike will announce that the board is requesting an increase in authorized share count. Price should stay around 90-95 cents up until earnings release. If Brazil approves comes in before the earnings report, look for a short lived spike and then return to the trading range of 90 cents -1.00. I think most of the carnage has happened as well , but I would love to get more shares to swing under a dollar 😊 |
|
